Cross-source evidence timeline

Desmopressin research timeline

Follow 101 selected, directly cited source records from February 21, 1978 through October 30, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

101Selected records
29Source years
3Evidence lanes
October 30, 2026Latest source date

Source year

2026

10 records
  1. Clinical trials

    ClinicalTrials.gov record NCT06020495↗

    PeptideScanner retained ClinicalTrials.gov record NCT06020495 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  2. Literature metadata

    Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis.↗

    PubMed lists PMID 35478451 in Reviews in endocrine & metabolic disorders as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2022-04-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis.↗

    PubMed lists PMID 42864513 in Neurocritical care as Journal Article, Review, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.↗

    PubMed lists PMID 35199198 in European journal of clinical pharmacology as Journal Article, Review, with publication-date metadata of 2022-02-23 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Desmopressin for nocturnal enuresis in children.↗

    PubMed lists PMID 40728007 in The Cochrane database of systematic reviews as Journal Article, Systematic Review, Meta-Analysis, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06635629↗

    PeptideScanner retained ClinicalTrials.gov record NCT06635629 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  7. Literature metadata

    Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.↗

    PubMed lists PMID 40176766 in Haematologica as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-04-03 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT06337838↗

    PeptideScanner retained ClinicalTrials.gov record NCT06337838 at 2026-11-16T01:33:21.554Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  9. Regulatory

    Drugs@FDA application ANDA219981↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 219981 with status AP dated 2026-02-27, and names desmopressin acetate among the application record's active ingredients.↗

  10. Regulatory

    Drugs@FDA application NDA219873↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 219873 with status AP dated 2026-02-25, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2025

4 records
  1. Literature metadata

    Desmopressin Withdrawal Strategy for Pediatric Enuresis: A Meta-analysis.↗

    PubMed lists PMID 27343233 in Pediatrics as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-06-24 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Desmopressin for treating nocturia in men.↗

    PubMed lists PMID 29055129 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S., Systematic Review, with publication-date metadata of 2017-10-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT05467033↗

    PeptideScanner retained ClinicalTrials.gov record NCT05467033 at 2026-11-16T01:33:21.554Z. Its registry update date was 2025-05-08, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  4. Literature metadata

    Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis.↗

    PubMed lists PMID 30216627 in BJU international as Journal Article, Review, Network Meta-Analysis, with publication-date metadata of 2018-10-31 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

5 records
  1. Regulatory

    Federal Register notice 2024-26913↗

    The Federal Register published notice 2024-26913, attributed to FDA and its parent HHS department, on 2024-11-19. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  2. Regulatory

    Federal Register notice 2024-25391↗

    The Federal Register published notice 2024-25391, attributed to FDA and its parent HHS department, on 2024-10-31. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  3. Literature metadata

    Desmopressin as a hemostatic and blood sparing agent in bleeding disorders.↗

    PubMed lists PMID 36656570 in European journal of haematology as Journal Article, Review, with publication-date metadata of 2023-02-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Drugs@FDA application ANDA213095↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213095 with status AP dated 2024-03-21, and names desmopressin acetate among the application record's active ingredients.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT04103034↗

    PeptideScanner retained ClinicalTrials.gov record NCT04103034 at 2026-11-16T01:33:21.554Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was desmopressin.↗

Source year

2023

8 records
  1. Literature metadata

    Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis.↗

    PubMed lists PMID 37928358 in Frontiers in pediatrics as Journal Article, Review, with publication-date metadata of 2023-10-19 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis.↗

    PubMed lists PMID 30425276 in Scientific reports as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2018-11-13 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis.↗

    PubMed lists PMID 37041092 in Journal of pediatric surgery as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review.↗

    PubMed lists PMID 37649925 in Cureus as Journal Article, Review, with publication-date metadata of 2023-08-29 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03389412↗

    PeptideScanner retained ClinicalTrials.gov record NCT03389412 at 2026-11-16T01:33:21.554Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  6. Regulatory

    Drugs@FDA application ANDA216904↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 216904 with status AP dated 2023-03-20, and names desmopressin acetate among the application record's active ingredients.↗

  7. Literature metadata

    Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.↗

    PubMed lists PMID 35839450 in Blood as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-09-08 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Regulatory

    Federal Register notice 2023-02442↗

    The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

Source year

2022

8 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01439997↗

    PeptideScanner retained ClinicalTrials.gov record NCT01439997 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-12-15, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  2. Regulatory

    Drugs@FDA application ANDA216922↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 216922 with status AP dated 2022-11-16, and names desmopressin acetate among the application record's active ingredients.↗

  3. Literature metadata

    Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis.↗

    PubMed lists PMID 35192687 in Blood advances as Journal Article, Meta-Analysis, Systematic Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-28 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Drugs@FDA application ANDA215961↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 215961 with status AP dated 2022-08-19, and names desmopressin acetate among the application record's active ingredients.↗

  5. Literature metadata

    Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach.↗

    PubMed lists PMID 35169370 in Medical archives (Sarajevo, Bosnia and Herzegovina) as Journal Article, Meta-Analysis, with publication-date metadata of 2021-12 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Desmopressin treatment for nocturia caused by nocturnal polyuria: practical guidelines.↗

    PubMed lists PMID 33552576 in Central European journal of urology as Journal Article, Review, with publication-date metadata of 2020-11-02 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.↗

    PubMed lists PMID 27443694 in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis as Journal Article, Review, with publication-date metadata of 2016-07-21 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT03201419↗

    PeptideScanner retained ClinicalTrials.gov record NCT03201419 at 2026-11-16T01:33:21.554Z. Its registry update date was 2022-03-02, and PeptideScanner's reviewed identity mapping was desmopressin.↗

Source year

2020

4 records
  1. Literature metadata

    Role of Desmopressin in the Critical Care Setting.↗

    PubMed lists PMID 32168509 in AACN advanced critical care as Journal Article, Review, with publication-date metadata of 2020-03-15 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Drugs@FDA application ANDA210223↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 210223 with status AP dated 2020-09-17, and names desmopressin acetate among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA210218↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 210218 with status AP dated 2020-02-14, and names desmopressin acetate among the application record's active ingredients.↗

  4. Literature metadata

    Perioperative Desmopressin for Patients Undergoing Otolaryngologic Procedures: A Systematic Review.↗

    PubMed lists PMID 30857487 in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery as Journal Article, Systematic Review, with publication-date metadata of 2019-03-12 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2019

10 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02904759↗

    PeptideScanner retained ClinicalTrials.gov record NCT02904759 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02905682↗

    PeptideScanner retained ClinicalTrials.gov record NCT02905682 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-09-11, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  3. Literature metadata

    [Treatment of nocturia in men with desmopressin].↗

    PubMed lists PMID 29492635 in Der Urologe. Ausg. A as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Drugs@FDA application ANDA208357↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 208357 with status AP dated 2019-06-06, and names desmopressin acetate among the application record's active ingredients.↗

  5. Literature metadata

    Desmopressin (Nocdurna and Noctiva) for nocturnal polyuria.↗

    PubMed lists PMID 31022158 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2019-03-25 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Federal Register notice 2019-10165↗

    The Federal Register published notice 2019-10165, attributed to FDA and its parent HHS department, on 2019-05-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  7. Literature metadata

    Desmopressin for treating nocturia in men.↗

    PubMed lists PMID 29489052 in BJU international as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2018-03-26 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Regulatory

    Drugs@FDA application ANDA091374↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 091374 with status AP dated 2019-02-14, and names desmopressin acetate among the application record's active ingredients.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT02584231↗

    PeptideScanner retained ClinicalTrials.gov record NCT02584231 at 2026-11-16T01:33:21.554Z. Its registry update date was 2019-02-06, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  10. Regulatory

    Drugs@FDA application ANDA210371↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 210371 with status AP dated 2019-01-28, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2018

3 records
  1. Literature metadata

    Combination treatment of nocturnal enuresis with desmopressin and indomethacin.↗

    PubMed lists PMID 27787700 in Pediatric nephrology (Berlin, Germany) as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-10-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02506023↗

    PeptideScanner retained ClinicalTrials.gov record NCT02506023 at 2026-11-16T01:33:21.554Z. Its registry update date was 2018-07-16, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  3. Regulatory

    Drugs@FDA application NDA022517↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 022517 with status AP dated 2018-06-21, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2017

11 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00223717↗

    PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  2. Regulatory

    Drugs@FDA application ANDA091345↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 091345 with status AP dated 2017-10-03, and names desmopressin acetate among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA204695↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 204695 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients.↗

  4. Regulatory

    Drugs@FDA application ANDA204751↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 204751 with status AP dated 2017-08-22, and names desmopressin acetate among the application record's active ingredients.↗

  5. Regulatory

    Federal Register notice 2017-16581↗

    The Federal Register published notice 2017-16581, attributed to FDA and its parent HHS department, on 2017-08-07. Its official title is “Product-Specific Guidances; Final Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT01552343↗

    PeptideScanner retained ClinicalTrials.gov record NCT01552343 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-07-11, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT02125188↗

    PeptideScanner retained ClinicalTrials.gov record NCT02125188 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  8. Regulatory

    Drugs@FDA application ANDA207880↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 207880 with status AP dated 2017-05-26, and names desmopressin acetate among the application record's active ingredients.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT01994330↗

    PeptideScanner retained ClinicalTrials.gov record NCT01994330 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  10. Regulatory

    Drugs@FDA application NDA201656↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 201656 with status AP dated 2017-03-03, and names desmopressin acetate among the application record's active ingredients.↗

  11. Literature metadata

    Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial.↗

    PubMed lists PMID 27117753 in Acta anaesthesiologica Scandinavica as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2016-04-27 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2016

1 record
  1. Regulatory

    Federal Register notice 2016-14418↗

    The Federal Register published notice 2016-14418, attributed to FDA and its parent HHS department, on 2016-06-20. Its official title is “Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

Source year

2015

4 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01223937↗

    PeptideScanner retained ClinicalTrials.gov record NCT01223937 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01262456↗

    PeptideScanner retained ClinicalTrials.gov record NCT01262456 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01606072↗

    PeptideScanner retained ClinicalTrials.gov record NCT01606072 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-08-28, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  4. Regulatory

    Drugs@FDA application ANDA201831↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 201831 with status AP dated 2015-05-28, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2014

3 records
  1. Regulatory

    Federal Register notice 2014-28702↗

    The Federal Register published notice 2014-28702, attributed to FDA and its parent HHS department, on 2014-12-09. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01435083↗

    PeptideScanner retained ClinicalTrials.gov record NCT01435083 at 2026-11-16T01:33:21.554Z. Its registry update date was 2014-12-05, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  3. Regulatory

    Drugs@FDA application ANDA200653↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 200653 with status AP dated 2014-06-27, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2013

2 records
  1. Regulatory

    Drugs@FDA application ANDA078271↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 078271 with status AP dated 2013-12-23, and names desmopressin acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA091280↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 091280 with status AP dated 2013-01-25, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2012

4 records
  1. Regulatory

    Federal Register notice 2012-30308↗

    The Federal Register published notice 2012-30308, attributed to FDA and its parent HHS department, on 2012-12-17. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01184859↗

    PeptideScanner retained ClinicalTrials.gov record NCT01184859 at 2026-11-16T01:33:21.554Z. Its registry update date was 2012-05-25, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  3. Regulatory

    Drugs@FDA application ANDA077212↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 077212 with status AP dated 2012-04-12, and names desmopressin acetate among the application record's active ingredients.↗

  4. Regulatory

    Federal Register notice 2012-4037↗

    The Federal Register published notice 2012-4037, attributed to FDA and its parent HHS department, on 2012-02-22. Its official title is “Final Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

Source year

2011

3 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01078753↗

    PeptideScanner retained ClinicalTrials.gov record NCT01078753 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00230594↗

    PeptideScanner retained ClinicalTrials.gov record NCT00230594 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was desmopressin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT00902265↗

    PeptideScanner retained ClinicalTrials.gov record NCT00902265 at 2026-11-16T01:33:21.554Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was desmopressin.↗

Source year

2010

1 record
  1. Regulatory

    Federal Register notice 2010-11038↗

    The Federal Register published notice 2010-11038, attributed to FDA and its parent HHS department, on 2010-05-11. Its official title is “Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

Source year

2009

2 records
  1. Regulatory

    Federal Register notice E9-28593↗

    The Federal Register published notice E9-28593, attributed to FDA and its parent HHS department, on 2009-12-01. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00902655↗

    PeptideScanner retained ClinicalTrials.gov record NCT00902655 at 2026-11-16T01:33:21.554Z. Its registry update date was 2009-05-15, and PeptideScanner's reviewed identity mapping was desmopressin.↗

Source year

2008

2 records
  1. Regulatory

    Federal Register rule E8-24050↗

    The Federal Register published rule E8-24050, attributed to FDA and its parent HHS department, on 2008-10-09. Its official title is “Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  2. Regulatory

    Drugs@FDA application NDA021795↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 021795 with status AP dated 2008-05-08, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2006

2 records
  1. Regulatory

    Drugs@FDA application ANDA077414↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 077414 with status AP dated 2006-03-07, and names desmopressin acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA077122↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 077122 with status AP dated 2006-01-25, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2005

2 records
  1. Regulatory

    Drugs@FDA application ANDA076470↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 076470 with status AP dated 2005-07-01, and names desmopressin acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA076703↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 076703 with status AP dated 2005-01-27, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2002

1 record
  1. Regulatory

    Drugs@FDA application NDA021333↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 021333 with status AP dated 2002-09-16, and names desmopressin acetate among the application record's active ingredients.↗

Source year

2000

3 records
  1. Regulatory

    Drugs@FDA application ANDA075220↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 075220 with status AP dated 2000-08-28, and names desmopressin acetate among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA074574↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 074574 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA074575↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 074575 with status AP dated 2000-02-18, and names desmopressin acetate among the application record's active ingredients.↗

Source year

1999

1 record
  1. Regulatory

    Drugs@FDA application ANDA074830↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 074830 with status AP dated 1999-01-25, and names desmopressin acetate among the application record's active ingredients.↗

Source year

1997

2 records
  1. Regulatory

    Federal Register notice 97-30614↗

    The Federal Register published notice 97-30614, attributed to FDA and its parent HHS department, on 1997-11-21. Its official title is “Determination That Desmopressin Acetate Nasal Solution 0.01% (for Refrigerated Storage) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.↗

  2. Regulatory

    Drugs@FDA application ANDA074888↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 074888 with status AP dated 1997-10-15, and names desmopressin acetate among the application record's active ingredients.↗

Source year

1995

1 record
  1. Regulatory

    Drugs@FDA application NDA019955↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 019955 with status AP dated 1995-09-06, and names desmopressin acetate among the application record's active ingredients.↗

Source year

1994

1 record
  1. Regulatory

    Drugs@FDA application NDA020355↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 020355 with status AP dated 1994-03-07, and names desmopressin acetate among the application record's active ingredients.↗

Source year

1990

1 record
  1. Regulatory

    Drugs@FDA application NDA019776↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 019776 with status AP dated 1990-12-26, and names desmopressin acetate among the application record's active ingredients.↗

Source year

1984

1 record
  1. Regulatory

    Drugs@FDA application NDA018938↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 018938 with status AP dated 1984-03-30, and names desmopressin acetate among the application record's active ingredients.↗

Source year

1978

1 record
  1. Regulatory

    Drugs@FDA application NDA017922↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 017922 with status AP dated 1978-02-21, and names desmopressin acetate among the application record's active ingredients.↗